| Revenue growth | 29% for FY26. |
|---|---|
| Margins | Targeting 28-30% EBITDA margins over 3 years. |
| Order book | 34 commercial molecules; 11 in Phase III/pre-registration. |
| Demand visibility | Clear visibility from large pharma strategic partnerships. |
| Management confidence | High, citing strong demand visibility and pipeline. |
Growth
FY26 revenue up 29%, EBITDA up 56%, PAT up 109%. CDMO segment grew 33%, CRO grew 24%.
Outlook
Guided 15-20% revenue growth and 28-30% EBITDA margins. Planned FY27 capex of ₹1,100-1,300 crores.
Risks
Geopolitical tensions affecting input costs/logistics; customer concentration (top 10 clients at 54% of revenue).
Earnings Call filed with BSE, NSE: SAILIFE. Summary written with AI assistance from the document.
Sai Life Science Ltd: key numbers
- Share price
- ₹1,558.10
- Market cap
- ₹33,097 Cr
- Revenue (annual)
- ₹2,192 Cr
- Net profit (annual)
- ₹348.9 Cr
- P/E (TTM)
- 91.5×Sector 47.4×
- Promoter holding
- 34.53%-0.08% QoQ
- FII holding
- 19.65%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sai Life Science Ltd
All →Sai Life Science Employee Stock Options
Sai Life Sciences Limited has announced the allotment of equity shares under its ESOP scheme. This allotment increases the company's paid-up share capital.
Sai Life Science Employee Stock Options
Sai Life Sciences allotted 24,000 shares upon exercise of ESOP 2008 options at ₹188.90 per share. This issuance increases the company's paid-up equity share capital.
- Value
- ₹0.45 Cr
Sai Life Science Annual General Meeting
Sai Life Sciences summarised proceedings of its 27th AGM held 17 Sep 2026. Shareholders adopted FY25-26 financials and re-appointed MD Krishnamraju Kanumuri.
Sai Life Science Employee Stock Options
Sai Life Sciences Limited allotted 80,600 equity shares under its ESOP/ESPS scheme. This increased the company's total paid-up share capital to ₹21.24 Crore.
Sai Life Science Employee Stock Options
Sai Life Sciences Limited allotted 80,600 equity shares following the exercise of options under its 2008 and 2018 ESOP plans. The total paid-up capital increased to ₹21.24 Crore.
- Value
- ₹0.43 Cr
Sai Life Science Other Announcement
Sai Life Sciences submitted its Business Responsibility and Sustainability Report (BRSR) and ESG Databook for the financial year 2025-26, as required by regulatory norms.